Brief: Ovid Therapeutics Q3 EPS USD -0.2 Vs. IBES Estimate USD -0.2
12/11/2024 13:00
Nov 12 (Reuters) - Ovid Therapeutics Q3 operating expenses USD 13.399 million. * Q3 net income USD -14.006 million * Q3 basic EPS USD -0.2
Recent news on Ovid Therapeutics
See all newsOvid Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Ovid Therapeutics Q2 revenue beats estimates
Brief: Ovid Therapeutics Q2 EPS USD -0.08
Ovid Therapeutics Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Ovid Therapeutics Appoints Leading Physician-Scientist And Biotech Innovator Anna Greka, M.D., Ph.D., To Board Of Directors